Drug Trial Radar · NCT07668375
Outcome of Treatment With Botulinum toxinA in Patients With Temporomandibular Myofascial Pain
Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
118
Actual
Start
Jan 2, 2026
Primary completion
Apr 1, 2026
Study completion Apr 1, 2026
Sponsor
- Lead sponsor
- PAEC General Hospital, IslamabadAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Purpose: The aim of this study is to investigate the effectiveness and patient reported outcomes (interincisal distance and temporomandibular myofascial pain) of treatment with intramuscularly administered BTX-A vs N/S in patients with temporomandibular myofascial pain. OBJECTIVES: To determine the outcome of treatment with botulinum toxin-A vs N/S in patients with temporomandibular myofascial pain.
Conditions
- Myofascial Pain - Dysfunction Syndrome of TMJ
Interventions
Botulinum Toxin-A (Botulax - letibotulinumtoxinA)Drug
In this study, intramuscular injection of Botulinum Toxin-A (50-100 units) would be administered to the patient using a 1 mL insulin syringe with a 26G needle at a dilution of 10 U/mL in normal saline. Injections would be given at 5 sites: 3 in the masseter muscle and 2 in the temporalis muscle, based on the patient's side of complaint (unilateral or bilateral). Topical lidocaine 5% cream would be applied before injection. The injection aims to reduce jaw muscle pain and increase interincisal mouth opening, allowing patients to resume normal daily activities without delay.
Normal SalineDrug
Intramuscular injection of normal saline (N/S) 1 mL would be administered at the same sites (masseter and temporalis muscles) as a placebo comparator. Normal saline injection would not be expected to significantly reduce pain intensity or increase interincisal mouth opening compared to BTX-A.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Measurement of post-injection pain in patients diagnosed with Temporomandibular Myofascial PainTime frame: From enrolment to 4, 8, and 12 weeks post-injection
- Measurement of Interincisal mouth opening in patients diagnosed with Temporomandibular Myofascial Pain.Time frame: From enrolment to 4, 8, and 12 weeks post-injection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PAEC General Hospital, Islamabad
Islamabad, Islamabad, Pakistan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.